Blood Cancers
Blood Cancers
Advertisement
Tamara ThomasBlood Cancers | December 6, 2023
Researchers found that Hispanic people were more likely to develop and die from ALL than Black and White people.
Read More
Cailin ConnerMultiple Myeloma | November 30, 2023
Hispanic patients with multiple myeloma had lower overall response rates to idecabtagene vicleucel.
Cailin ConnerBlood Cancers | November 28, 2023
Advanced age, financial constraints contribute to higher discontinuation rates among elderly Medicare beneficiaries.
Cailin ConnerBlood Cancers | November 15, 2023
Breastfeeding has a protective effect against acute lymphoblastic leukemia in young children.
Cailin ConnerBlood Cancers | November 1, 2023
Study suggests significant associations between nonchromosomal birth defects and childhood leukemia.
Cailin ConnerBlood Cancers | October 16, 2023
Vitamin C and D supplementation for the treatment of AML, was associated with reduced infection rates.
Patrick DalyMultiple Myeloma | October 17, 2023
Modifying or ceasing MM treatment based on negative MRD status may be a promising approach for newly diagnosed patients.
Patrick DalyMultiple Myeloma | October 17, 2023
White patients with MM and diabetes showed worse survival outcomes, but this association was not found in Black patients.
Patrick DalyMultiple Myeloma | October 17, 2023
Phase 1 data showed promising outcomes with elranatamab in MM, and authors recommend a phase 2 dose of 76 mg weekly.
Patrick DalyMultiple Myeloma | October 17, 2023
Patients with MM and renal impairment on DVd showed safety and efficacy comparable with patients without renal impairment.
Cailin ConnerBlood Cancers | October 2, 2023
The prognosis for induction failure in childhood T-cell ALL remains unfavorable despite advancements in treatment.
Patrick DalyMultiple Myeloma | October 17, 2023
Higher creatinine levels and decompression surgery without fusion were linked to complications after spinal surgery in MM.
Patrick DalyMultiple Myeloma | October 17, 2023
The phase 1/2 MajesTEC-1 study established a recommended dose for subcutaneous teclistamab in relapsed or refractory MM.
Patrick DalyMultiple Myeloma | October 17, 2023
Prior allogeneic stem cell transplantation did not appear to impact the safety and efficacy of cilta-cel treatment for MM.
Cailin ConnerBlood Cancers | September 15, 2023
Being overweight or obese was associated with increased toxicity and higher nonrelapse mortality.
Cailin ConnerBlood Cancers | September 27, 2023
Sociodemographic factors lead to disparities in outcomes for multiple myeloma patients.
Patrick DalyMultiple Myeloma | October 17, 2023
IMWG multiple myeloma treatment guidelines informed by studies with a major lack of Black patients, study finds.
Tamara ThomasBreast Cancer | August 18, 2023
Researchers discovered that breast cancer survivors had a heightened risk of being diagnosed with pericarditis.
Cailin ConnerBlood Cancers | August 15, 2023
The insurance status of patients with AML impacted access to molecular genetic sequencing and overall survival.
Patrick DalyMultiple Myeloma | October 17, 2023
Daratumumab added to carfilzomib-lenalidomide-dexamethasone triplet therapy for multiple myeloma improved MRD and survival.
Advertisement
Advertisement
Latest News

February 28, 2024

Advertisement